PTPI

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.0009
Percentage change -1.31	%

Peers: AMPH ACRS OKUR VTGN OCUL CARA CNTX IRD RDHL

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.62	Insider Own	18.16%	Shs Outstand	29.93M	Perf Week	-21.40%
Market Cap	3.62M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	24.49M	Perf Month	-28.09%
Income	-26.80M	PEG	-	EPS next Q	-	Inst Own	3.25%	Short Float	3.04%	Perf Quarter	-85.54%
Sales	5.11M	P/S	0.71	EPS this Y	-	Inst Trans	3.41%	Short Ratio	0.02	Perf Half Y	-80.41%
Book/sh	-0.71	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.75M	Perf Year	-92.73%
Cash/sh	0.07	P/C	0.98	EPS next 5Y	-	ROE	-	52W Range	0.05 - 1.00	Perf YTD	-82.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	55.46%	ROI	-	52W High	-93.23%	Beta	2.03
Dividend TTM	-	Quick Ratio	0.33	Sales past 5Y	-19.05%	Gross Margin	20.89%	52W Low	24.72%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.40	EPS Y/Y TTM	41.73%	Oper. Margin	-201.41%	RSI (14)	40.53	Volatility	29.57% 21.78%
Employees	18	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-524.20%	Recom	1.00	Target Price	1.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	55.57%	Payout	-	Rel Volume	0.09	Prev Close	0.07
Sales Surprise	0.01%	EPS Surprise	0.00%	Sales Q/Q	-56.68%	Earnings	-	Avg Volume	36.22M	Price	0.07
SMA20	-18.14%	SMA50	-55.59%	SMA200	-77.82%	Trades		Volume	1,414,470	Change	-1.31%

Mar-20-25 09:15AM	Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications (ACCESSWIRE) +5.85%
Feb-25-25 09:20AM	Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study (ACCESS Newswire)
Feb-18-25 09:25AM	Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants (ACCESSWIRE) -53.48%
Jan-07-25 09:15AM	Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules (ACCESSWIRE)
Dec-19-24 09:15AM	Petros Pharmaceuticals Featured in 'New Era of Healthcare, AI, Data and Consumer Empowerment' (ACCESSWIRE) -11.11%
09:00AM	Loading…
Dec-17-24 09:00AM	Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually (ACCESSWIRE) +87.27%
Oct-19-24 05:28PM	Petros Pharmaceuticals Amends Presidents Employment Terms (TipRanks)
Sep-11-24 09:15AM	Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) (ACCESSWIRE)
Sep-03-24 09:00AM	Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Aug-16-24 09:53PM	PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
Jul-29-24 09:20AM	Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) (ACCESSWIRE)
Jul-16-24 09:00AM	Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance (ACCESSWIRE) -6.23%
May-29-24 09:00AM	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch (ACCESSWIRE)
May-21-24 09:15AM	Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA (ACCESSWIRE)
May-16-24 10:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.30%
09:15AM	Loading…
May-14-24 09:15AM	Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe (ACCESSWIRE)
07:00AM	Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals (GlobeNewswire)
Apr-25-24 10:20AM	Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health (News Direct)
Apr-23-24 09:15AM	Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health (ACCESSWIRE)
Apr-16-24 09:15AM	Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) (ACCESSWIRE) -9.97%
Apr-02-24 09:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -23.57%
09:15AM	Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status (ACCESSWIRE)
Mar-19-24 09:00AM	Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Mar-11-24 07:00AM	BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc (News Direct)
Feb-14-24 09:15AM	Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Jan-24-24 09:15AM	Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch (ACCESSWIRE) -8.00%
Jan-17-24 09:00AM	Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch (ACCESSWIRE)
Dec-12-23 10:00AM	Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status (ACCESSWIRE) +7.33%
09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestors (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
Dec-05-23 09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
09:15AM	Loading…
Oct-30-23 09:15AM	Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) (ACCESSWIRE)
Oct-19-23 09:00AM	Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA (ACCESSWIRE)
Oct-04-23 09:00AM	Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label (ACCESSWIRE) -8.82%
Sep-28-23 08:00AM	Petros Pharmaceuticals to Present at the LD Micro Main Event XVI (ACCESSWIRE)
Sep-11-23 09:00AM	Petros Pharmaceuticals Provides Letter to Shareholders (ACCESSWIRE) +6.21%
Sep-06-23 04:05PM	Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Jul-13-23 04:30PM	Petros Pharmaceuticals Announces Capital Raise of $15 Million (ACCESSWIRE) -6.60% -10.03%
Nov-30-22 12:45PM	Petros Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Nov-15-22 08:00AM	Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update (ACCESSWIRE)
Oct-25-22 09:00AM	New FDA-Approved Labeling for Petros Pharmaceuticals STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy (ACCESSWIRE) +38.81%
Oct-21-22 08:00AM	Petros Pharmaceuticals to Participate in Two October 2022 Conferences (ACCESSWIRE)
Aug-15-22 08:00AM	Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 (ACCESSWIRE)
Jul-28-22 10:27AM	Petros Pharmaceuticals Responds to Fraudulent Press Release (GlobeNewswire)
09:25AM	Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share (GlobeNewswire)
Jul-19-22 09:15AM	Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky (GlobeNewswire)
May-16-22 05:00PM	Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 09:23AM	Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Companys Novel Topical Investigational Treatment for Peyronies Disease Which Impacts More Than 1 in 10 Men in the US (GlobeNewswire) +7.21%
Apr-27-22 09:25PM	Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022 (GlobeNewswire)
09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-26-22 09:15AM	Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology (GlobeNewswire) -10.24%
Apr-19-22 09:15AM	Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil) (GlobeNewswire) +20.91%
Apr-01-22 07:00AM	Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights (GlobeNewswire) -6.41%
Mar-03-22 08:00AM	Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference (GlobeNewswire)
Feb-01-22 09:15AM	Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health (PR Newswire)
Jan-24-22 09:15AM	Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States (PR Newswire) +10.60%
Jan-18-22 09:20AM	Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) -11.45%
Jan-06-22 04:30PM	Petros Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference and the Biotech Showcase 2022 (PR Newswire)
Jan-05-22 01:38PM	Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ... (GuruFocus.com) -9.15%
Dec-28-21 09:15AM	Petros Pharmaceuticals Announces Closing of $7.5 Million Offering (PR Newswire) +9.27%
Dec-22-21 09:10AM	Petros Pharmaceuticals Announces $7.5 Million Offering (PR Newswire) -18.34%
Dec-08-21 09:15AM	Petros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) +7.69%
Dec-02-21 12:00PM	Petros Pharmaceuticals Announces Closing of $10 Million Offering (PR Newswire) +10.68%
Nov-30-21 09:00AM	Petros Pharmaceuticals Announces $10 Million Offering (PR Newswire) -28.50%
Nov-15-21 04:30PM	Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire) -22.02%
Nov-11-21 09:15AM	Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference (PR Newswire)
Nov-08-21 09:15AM	Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease (PR Newswire)
Nov-03-21 09:16AM	Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales (PR Newswire) +64.57%
Oct-21-21 09:25AM	Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show (PR Newswire)
Oct-19-21 09:25AM	Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering (PR Newswire)
Oct-14-21 09:00AM	Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering (PR Newswire)
Sep-23-21 08:30AM	Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 08:30AM	Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-17-21 09:25AM	Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales (PR Newswire) -7.75%
Aug-16-21 08:30AM	Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 (ACCESSWIRE) -10.26%
Aug-12-21 08:00AM	Petros Pharmaceuticals to Present at Two Upcoming August Conferences (PR Newswire)
Aug-11-21 10:39AM	Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit (Newsfile)
Jul-27-21 09:25AM	FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA® (PR Newswire)
Jul-13-21 09:15AM	Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment (PR Newswire)
Jul-12-21 08:15AM	Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021 (PR Newswire)
Jun-02-21 10:12AM	Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 (PR Newswire)
May-17-21 08:22AM	Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales (PR Newswire) +5.74%
May-14-21 08:30AM	Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021 (PR Newswire)
May-07-21 08:00AM	Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021 (PR Newswire) +5.59%
Mar-18-21 09:00AM	Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling (PR Newswire)
Feb-18-21 08:00AM	Petros Pharmaceuticals Welcomes Dr. Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire) -9.22%
Feb-04-21 08:30AM	Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire)
Jan-19-21 08:00AM	Petros Pharmaceuticals to Participate in NobleCon17 (GlobeNewswire)
Dec-08-20 04:15PM	Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc. (PR Newswire)

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Petros Pharmaceuticals Inc

Upgrade your FINVIZ experience